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 ABSTRACT 
 Elevation of ketone bodies in dairy cows frequently 
occurs in early lactation, usually concomitantly with a 
lack of energy and glucose. The objective of this study 
was to induce an elevated plasma β-hydroxybutyrate 
(BHBA) concentration over 48 h in mid-lactating dairy 
cows (i.e., during a period of positive energy balance 
and normal glucose plasma concentrations). Effects 
of BHBA infusion on feed intake, metabolism, and 
performance were investigated. Thirteen cows were 
randomly assigned to 1 of 2 infusion groups, includ-
ing an intravenous infusion with Na-dl-β-OH-butyrate 
(1.7 mol/L) to achieve a plasma concentration of 1.5 
to 2.0 mmol/L of BHBA (HyperB; n = 5), or an infu-
sion of 0.9% saline solution (control; n = 8). Blood was 
sampled before and hourly during the 48 h of infusion. 
In the liver, mRNA transcripts related to gluconeo-
genesis (pyruvate carboxylase, glucose 6-phosphatase, 
mitochondrial phosphoenolpyruvate carboxykinase), 
phosphofructokinase, pyruvate dehydrogenase complex, 
and fatty acid synthesis (acetyl-coenzyme A carboxyl-
ase, fatty acid synthase) were measured by real-time 
PCR. Glyceraldehyde-3-phosphate dehydrogenase and 
ubiquitin were used as housekeeping genes. Changes 
(difference between before and after 48-h infusion) 
during the infusion period were evaluated by ANOVA 
with treatment as fixed effect, and area under the curve 
of variables was calculated on the second day of ex-
periment. The plasma BHBA concentration in HyperB 
cows was 1.74 ± 0.02 mmol/L (mean ± SE) compared 
with 0.59 ± 0.02 mmol/L for control cows. The change 
in feed intake, milk yield, and energy corrected milk 
did not differ between the 2 experimental groups. Infu-
sion of BHBA reduced the plasma glucose concentra-
tion (3.47 ± 0.11 mmol/L) in HyperB compared with 
control cows (4.11 ± 0.08 mmol/L). Plasma glucagon 
concentration in HyperB was lower than the control 
group. All other variables measured in plasma were not 
affected by treatment. In the liver, changes in mRNA 
abundance for the selected genes were similar between 
2 groups. Results demonstrate that intravenous infu-
sion of BHBA decreased plasma glucose concentration 
in dairy cows, but this decrease could not be explained 
by alterations in insulin concentrations or key enzymes 
related to gluconeogenesis. Declined glucose concentra-
tion is likely functionally related to decreased plasma 
glucagon concentration. 
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 INTRODUCTION 
 High-yielding dairy cows need a lot of energy and 
nutrients for maintenance and milk synthesis during 
peak lactation, in particular. Despite increased feed 
intake in early lactation (Agenäs et al., 2003), after 
the periparturient nadir this adaptation cannot cover 
the requirements during this period. Typical metabolic 
changes during this period of negative energy balance 
are low plasma concentrations of glucose and high con-
centrations of plasma NEFA, as well as a subsequent 
elevation of ketone bodies (van Dorland et al., 2009; 
Gross et al., 2011). Although ketone bodies can be used 
as an alternative fuel for some tissues, such as brain 
and heart (Laffel, 1999; Veech, 2004), kidney (Weide-
mann and Krebs, 1969), skeletal muscles (Ruderman 
and Goodman, 1973) and lactating mammary glands 
(Shaw, 1943), the utilization of ketone bodies is limited. 
Unused ketone bodies concentration increase tremen-
dously in blood (Duffield et al., 2009). This elevation of 
ketone bodies in blood causes reduced feed intake and 
increases the risk of clinical ketosis, displaced aboma-
sums, metritis, and subsequent decrease of milk produc-
tion (Duffield et al., 2009). The most used method to 
detect subclinical ketosis is the measurement of BHBA 
in serum or plasma (Duffield, 2000; Herdt, 2000); in 
ruminants, BHBA is the major ketone body found in 
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circulation (Bergman, 1971). Ospina et al. (2010) sug-
gested a threshold value of 1,200 μmol/L to distinguish 
between normal cows and subclinical ketotic cows.
Subcutaneous BHBA infusion in rats (Moore et al., 
1976; Langhans et al., 1983), intraperitoneal BHBA 
infusion in goats (Rossi et al., 2000), and intracere-
broventricular BHBA infusion in dairy cows (Kuhla et 
al., 2011) led to inhibited feed intake in these animals. 
Intravenous BHBA infusion led to decreased plasma 
concentration of glucose in dogs (Madison et al., 1964), 
pigs (Müller et al., 1984), and ewes (Schlumbohm and 
Harmeyer, 2003, 2004). The reason for declined glu-
cose during the infusion of BHBA remains unclear, but 
those authors suggested that infusion of BHBA induced 
hypoglycemia through direct or indirect inhibition of 
gluconeogenesis, or by a change in the insulin concen-
tration in pig and sheep (Müller et al., 1984; Schlum-
bohm and Harmeyer, 2004). This mechanism has not 
yet been investigated in dairy cows. Our objective was 
to induce an elevated plasma BHBA concentration 
over 48 h and to investigate its effects on feed intake, 
performance, and metabolism in the dairy cow. More 
specifically, this study was carried out to confirm that 
in the dairy cows, as in sheep and pigs, elevated plasma 
BHBA concentration affects plasma glucose concentra-
tion, and to investigate the underlying mechanisms.
MATERIALS AND METHODS
Animals and Management
The current trial followed the guidelines of Swiss Law 
on Animal Protection permitted by the Committee of 
Animal Experiments of the Canton Fribourg, Switzer-
land. The study was carried out with 13 diestrus Hol-
stein dairy cows with a parity of 3.5 ± 0.10 at 28 ± 0.3 
(mean ± SD) wk in milk. Cows in later lactation were 
selected to allow the investigation of the specific effect 
of BHBA infusion without influences of the characteris-
tic endocrine and metabolic changes during the transi-
tion period. The cows were healthy at the start of the 
experiment, which was confirmed by a routine blood 
glutaraldehyde coagulation test (Sandholm, 1976) and 
by measuring milk SCC (DeLaval cell counter DCC, 
DeLaval International AB, Tumba, Sweden), which had 
to be less than 150,000 cells/mL in all 4 quarters.
Two weeks before the start of the experiment, ani-
mals were allowed to adapt to tiestall housing and to 
the experimental feeding conditions. Animals were 
fed ad libitum with hay. In addition, cows were fed 
a protein- and energy-rich concentrate (barley 23.5%, 
oats 14.0%, wheat bran 20.0%, expeller soybean 17.0%, 
linseed meal 15.0%, salt livestock 0.6%, carbonate of 
lime 2.2%, kaf premix 0.4%, molasses 4.0%, and alikon 
3.0%) twice daily according to each cow’s individual 
extra energy requirement for milk production, and 50 g 
of minerals once daily. Water was available ad libitum. 
Milking was performed twice daily at 0530 and 1600 h.
Experimental Design and Treatments
The 13 cows were randomly assigned to one of 2 
infusion treatments. The treatments included (1) an 
infusion with BHBA (HyperB; n = 5) to obtain 
a plasma BHBA concentration between 1.5 to 2.0 
mmol/L and (2) an infusion with a 0.9% saline solu-
tion (NaCl, 20 mL/h; control; n = 8). One day before 
the infusions started, cows were fitted with indwelling 
intravenous catheters (Cavafix Certo Splittocan, B. 
Braun Melsungen AG, Melsungen, Germany) with a 
length of 32 cm and a diameter of 16 gauge in both 
jugular veins. The infusions through one of the cath-
eters started at 0900 h and continued until 0900 h two 
days later. The initial infusion rate (8.5 ± 0.6 μmol/kg 
per min) was determined on the basis of BW of each 
animal and the molarity of the solution was followed 
by instant continued adjustments throughout the 48 
h to maintain a plasma BHBA concentration between 
1.5 to 2.0 mmol/L by a peristaltic pump (Perpex Ju-
bile pump, H. J. Guldener, Zürich, Switzerland). Dur-
ing the first 2 h of BHBA infusion, the blood samples 
were taken every 15 min to measure the plasma BHBA 
concentration and adjust the BHBA infusion rate to 
reach the plasma BHBA concentration between 1.5 
and 2.0 mmol/L. The control cows were treated with 
0.9% saline solution at an infusion rate of 20 mL/h 
administered using an automatic pump (Perfuser, B. 
Braun Melsungen AG).
Preparation of the BHBA Solution
To achieve a 1.7 M BHBA solution, 279.053 g of dl-
BHBA acid sodium salt (H6501, Sigma-Aldrich, Basel, 
Switzerland) was dissolved in bi-distilled water to reach 
an amount of 1.0 L, followed by homogenization using 
a rotor mixer for 10 to 20 min. The pH of the solution 
was adjusted with HCl to 7.4 and sterilized at 100 kPa 
and 131°C for 50 min. The solution was filtered through 
a 0.2-μm filter (Millipore Express Plus Membrane 45 
mm, Millipore, Billerica, MA) and stored at 4°C until 
infusion.
Data Collection and Sampling
Feed and Milk Samples. The individual intake of 
hay was recorded daily for each cow by weighing the 
amount given and subtracting it by the remainder of 
hay found the next morning. The milk yield was record-
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ed for each cow individually at every milking during the 
adaptation and experimental period. Proportional milk 
samples were taken during milking in the afternoon and 
in the morning before the start of the experimental 
infusions. The milk sampling was repeated in the after-
noon of d 2 (32 h after the start of infusion), and at the 
morning milking at the end of experiment.
Blood Samples. One week before the experiment, 
and immediately before the start of the experimental 
infusions on d 1, reference blood samples of each cow 
were taken from a jugular vein via vacuum tubes con-
taining tri-potassium-EDTA at 0730 h, after milking 
and before feeding. The tubes were kept on wet ice until 
they were centrifuged for 20 min at 3,000 × g and the 
plasma was obtained. Until the samples were analyzed 
for concentrations and activities of plasma variables, 
the plasma was frozen at −20°C. After analysis, the 
mean value of these samples was calculated and used as 
the reference concentration in the statistical evaluation. 
During the experimental infusions, blood samples were 
obtained from the contralateral jugular catheter, which 
was not used for the infusion, by using tubes containing 
tri-potassium-EDTA. The collected blood samples were 
partly analyzed immediately for BHBA concentration 
(described under Laboratory Procedures) as a basis 
for adjustments of the infusion rate, or were handled 
similar to the reference samples.
Liver Biopsies. One week before the infusions and 
48 h after the start of the infusions, following the blood 
sampling at around 0800 h, a liver biopsy was taken. 
Liver tissue (60–100 mg) was obtained under local an-
esthesia with 10 mL of Lidocain 2% (Streuli Pharma 
AG, Uznach, Switzerland) by blind liver puncture 
with a 14-gauge and 150 mm or 200 mm long biopsy 
needle (Tru-Cut, Provet AG, Lyssach, Switzerland). 
The samples were placed directly into RNA stabiliza-
tion reagent (RNAlater, Ambion, Applied Biosysthems, 
Austin, TX), kept at 5°C for 24 h, and then stored at 
−80°C until RNA extraction.
Laboratory Procedures
Feed and Milk. The nutritional composition of hay 
(DM content, 890g/kg of fresh matter; on DM basis, 
consisting of 153 g of CP/kg, 235.0 g of crude fiber/kg, 
and 5.7 MJ of NEL/kg) and concentrate (DM content, 
881 g/kg of fresh matter; on DM basis, consisting of 
217 g of CP/kg, 73.9 g of crude fiber/kg, and 7.6 MJ 
of NEL/kg) were determined by using routine analyses 
as described by van Dorland et al. (2009). The nutri-
tive energy balance was calculated as the difference 
between the energy intake, and the energy output [NEL, 
requirements for maintenance and milk production, 
determined from tabulated values and recommended 
equations according as to van Dorland et al. (2009)].
Milk samples were analyzed at the laboratory of the 
Holstein Association of Switzerland (Grangeneuve, 
Switzerland) for content of fat, protein, lactose, and 
urea (CombiFoss 6000, Gerber Instrument AG, Effre-
tikon, Switzerland). The ECM was calculated based on 
Sjaunja et al. (1991), using the formula ECM (kg/d) = 
{[0.038 × Fat (g/kg) + 0.024 × Protein (g/kg) + 0.017 
× Lactose (g/kg)] × Milk Yield [kg/d]}/3.14.
Blood Plasma. Plasma metabolites were measured 
enzymatically with an automated analyzer (Cobas Mira 
2, Hoffmann-La Roche, Basel, Switzerland) by the use 
of commercial kits as described by van Dorland et al. 
(2009) and Kreipe et al. (2011). Plasma insulin and 
IGF-1 were measured by RIA as described by Vicari 
et al. (2008), and total cortisol was measured by RIA 
as described by Blum et al. (1985). Plasma glucagon 
concentration was measured by using a RIA kit (cat. 
#GL-32K, Millipore, Zug, Switzerland).
Liver Tissue. Total mRNA was extracted from liver 
samples using peqGOLD TriFast (PEQLAB Biotech-
nologie GmbH, Erlangen, Germany) according to the 
manufacturer’s protocol, and afterward quantity and 
purity were determined by absorbance at 260 and 280 
nm using a NanoDrop ND-2000 spectrophotometer 
(NanoDrop Technologies Inc., Wilmington, DE). Sub-
sequently, 1 μg of total mRNA was reverse transcribed 
with 200 U of Moloney Murine Leukemia Virus Reverse 
Transcriptase RNAase H Minus, Point Mutant (Pro-
mega Corp., Madison, WI) using 100 pmol of random 
hexamer primers (Invitrogen, Leek, the Netherlands). 
A master mix was prepared containing the following 
components: 0.8 μL of PCR water, 1.0 μL of forward 
primer (5 pmol), 1.0 μL of reverse primer (5 pmol), 5.2 
μL of 2× SensiMix plus SYBR-Green (1 mM MgCl2). 
The selected and measured genes encoding for hepatic 
enzymes involved in gluconeogenesis, glycolysis, FA 
oxidation, citrate synthase, FA and triglyceride syn-
thesis, cholesterol synthesis, pyruvate dehydrogenase 
complex, and ketogensis are shown in Table 1. The 
primer sequences for pyruvate carboxylase (PC) and 
mitochondrial phosphoenolpyruvate carboxykinase 
were according to Hammon et al. (2003); FA synthase, 
acyl-CoA synthetase long-chain, carnitine palmitoyl-
transferase 1A, and citrate synthase were according 
to van Dorland et al. (2009); acetyl-CoA carboxylase 
(ACoAC), carnitine palmitoyltransferase 2, glucose-
6-phosphatase, and 3-hydroxyl-3-methylglutaryl-CoA 
synthase 1 (HMGCS1) were according to Graber et 
al. (2010). Lactate dehydrogenase A, lactate dehydro-
genase B, phosphofructokinase-liver, dihydrolipoamide 
branched chain transacylase E2, dihydrolipoamide 
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dehydrogenase, pyruvatedehydrogenase (lipomide) α 
1, glucagon receptor, glycogen synthase 2, and protein 
kinase AMP-activated α 1 (PRKAA1) primers were 
designed to amplify cDNA.
The PCR quantification was performed by using a 
Rotor-Gene 6000 (Corbett Research, Sydney, Austra-
lia), using the software version 1.7.40. Fluorescence 
take-off was calculated with the threshold program op-
Table 1. Polymerase chain reaction primer information (for = forward, rev = reverse), annealing temperature, and the PCR product length 
Gene1 Sequence 5?-3?2








 G6PC for GCCAACCTACAGATTTCGGTG NM-001076124 58 140
rev CAATGCCTGACAAGACTCCAG
 PC for ATCTCCTACACGGGTGACGT NM_177946 60 214
rev TGTCGTGGGTGTGGATGTGCA
 PEPCKm for TACGAGGCCTTCAACTGGCGT XM_583200 60 365
rev AGATCCAAGGCGCCTTCCTTA
Phosphofructokinase, liver and lactate  
dehydrogenase
 LDHA for CGGTTCACAAACAAGTGGTTG NM-174099 60 166
rev GAGACCCTTAATCATGGTGG
 LDHB for CAGCATTCTGGGAAAGTCTC NM-174100 60 141
rev GAGTAATCTTTGTCTGCCAC
 PFKL for TTGACTGCAGGACCAACGTC NM-001080244 60 120
rev GCAGCTTCTCCGACATCCAG
Glucagon receptor, glycogen synthase, 
protein kinase AMP-activated α 1
 GCGR for TCCCAGTGTCAGATGGATGA NM-001192414 60 207
rev CTTGAGCATGAAGGACACGA
 GYS2 for AAACTTCCTGCTGAGGATGC NM-001192905 58 138
rev GAATGTGCAGTGTCCCATAG
 PRKAA1 for AAACTGTACCAGGTCATCAG NM-001109802 58 326
rev GAAATTACTTCTGGTGCAGC
Pyruvate dehydrogenase complex variables
 DBT for GTCGCCTTGCAATGGAAAAC NM-173905 60 248
rev GTGAAAGCCTTTCACGGGTTC
 DLD for TGGTCAAGAGAGGCCATTTC NM-001206170 60 16
rev AACTGGGCAGCTTTAATAGC
 PDHA1 for ACACAGCATGAGTGATCCTG NM-001101046 60 127
rev CTTCAACACTGGCGAGATTG
FA and cholesterol synthesis-related variables
 ACoAC for CTCTTCCGACAGGTTCAAGC AJ-132890 61 248
rev ACCATCCTGGCAAGTTTCAC
 FASN for CTGAGTCGGAGAACCTGGAG NM_001012669 63 232
rev ACAATGGCCTCGTAGGTGAC
 HMGCS1 for TGTACGGCTCCCTGGCTTCTG BC-102850 60 313
rev CATGTTCCTTCGAAGAGGGAATC
FA oxidation-related variables
 ACSL1 for TGACTGTTGCTGGAGACTGG NM-001076085 61 199
rev CAGCCGTCTTTATCCAGAGC
 CPT1A for CAAAACCATGTTGTACAGCTTCCA BF039285 54 111
rev GCTTCCTTCATCAGAGGCTTCA
 CPT2 for CAGCCTGCCCAGGCTGCCTAT BC105423 60 163
rev AGTGACCAGCTGCTCATGCA
Citrate synthase and ketogenesis- 
related variables
 CS for TGGACATGATGTATGGTGG BC-114138 60 217
rev AGCCAAGATACCTGTTCCTC
 HMGCS2 for TCTGGCCCATCACTCTGCC NM-001045883 60 126
rev AGTGGGGAGCCTGGAGAAGC
1G6PC = glucose-6-phosphatase; PC = pyruvate carboxylase; PEPCKm = mitochondrial phosphoenolpyruvate carboxykinase; LDHA = lac-
tate dehydrogenase A; LDHB = lactate dehydrogenase B; PFKL = phosphofructokinase liver; GCGR = glucagon receptor; GYS2 = glycogen 
synthase 2; PPKA1 = protein kinase AMP-activated α 1; DBT = dihydrolipoamide branched chain transacylase E2; DLD = dihydrolipoamide 
dehydrogenase; PDHA1 = pyruvatedehydrogenase (lipomide) α 1; ACoAC = acetyl-CoA carboxylase; FASN = fatty acid synthase; HMGCS1 = 
3-hydroxyl-3-methylglutaryl-CoA synthase 1; ACSL1 = acyl-CoA synthetase long-chain; CPT1A = carnitine palmitoyltransferase 1A; CPT2 = 
carnitine palmitoyltransferase 2; CS = citrate synthase; HMGCS2 = 3-hydroxyl-3-methylglutaryl-CoA synthase 2.
2for = forward; rev = reverse.
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tion. Eight microliters of master mix and 2 μL of sample 
volume, containing 20 ng of cDNA, were used. A 3-step 
PCR program was performed with (1) denaturation for 
10 min at 95°C, (2) 40 cycles of amplification (each 
consisting of 15 s at 95°C, the primer-specific annealing 
temperature for 30 s; Pfaffl et al., 2002; Graber et al., 
2010) and extension at 72°C for 20 s and quantifica-
tion of fluorescence, and (3) a melting curve program 
(60–95°C). The mRNA levels were calculated relative 
to the mean expression level of the housekeeping genes 
GAPDH and ubiquitin, which were stable across time 
points as described by Kreipe et al. (2011).
Statistical Analysis
Prior to data analysis, the change (Δ) for each vari-
able (gene expression, plasma metabolites, feed intake, 
milk yield, and ECM) was calculated by subtracting 
the value measured after the infusion treatments from 
the value measured before the infusion treatments. The 
Δ for each variable (difference between before and af-
ter 48-h infusion) was statistically evaluated using the 
general linear models procedure of SAS (SAS Institute 
Inc., Cary, NC, 2002–2008, Release 9.2), including 
treatment (BHBA or NaCl) as fixed effect. Differences 
between means were determined by the Tukey test. 
In addition, means of Δ values obtained within each 
treatment were tested for their difference from zero. 
Furthermore, blood plasma variables and the area 
under the curve was calculated for d 2 of the treat-
ments and subsequently assessed statistically with the 
model as described above. Data obtained before the 
treatment were included as covariates in the model to 
compensate for initial differences between individuals. 
Data are presented as means ± SEM, and differences 
were considered significant if P < 0.05 and as a trend 
if P < 0.10.
RESULTS
Infusion Rates and Plasma Concentrations of BHBA
The mean infusion rate of BHBA over 48 h was 8.5 
± 0.6 μmol/kg per min (Figure 1). The mean plasma 
BHBA concentration reached and maintained was 1.7 
± 0.1 mmol/L for 48 h. The infusion of BHBA resulted 
in a marked increase in plasma BHBA concentration in 
HyperB cows (P < 0.001). Plasma BHBA concentration 
in control cows remained unchanged. Consequently, 
larger are under the curve was observed (Table 2) for 
plasma BHBA concentration in HyperB (1.74 ± 0.02 
mmol/L) cows compared with the control cows (0.59 ± 
0.02 mmol/L) on d 2 (P < 0.001).
Feed Intake, Energy Balance, and ECM
Dry matter intake of hay and concentrate before 
the infusions (d 0) is shown in Table 3. On d 1 of 
the infusions, DMI of hay and concentrate was 19.1 ± 
0.4 and 16.9 ± 1.9 kg/d for HyperB and control cows, 
respectively. On d 2 of the infusions, DMI of hay and 
concentrate was 19.0 ± 0.9 and 17.9 ± 1.0 kg/d for 
HyperB and control cows, respectively. The DMI was 
not affected by BHBA infusion.
The nutritive energy balance was not affected by 
BHBA infusion and was similar in both groups across 
the study period. The Δ from d 0 to d 2 was −1.04 ± 
8.67 and 1.72 ± 4.9 MJ/d for HyperB and control cows, 
respectively. Milk yield and ECM were not affected by 
BHBA infusion.
Blood Metabolites and Enzymes
Plasma glucose concentration in HyperB cows de-
creased (P = 0.03; Table 4) and was lower compared 
with control group on d 2 (P = 0.0012; Table 2 and 
Figure 2). β-Hydroxybutyrate infusion decreased the 
plasma glucagon concentration on d 2 (P = 0.03; Fig-
ure 3). Plasma concentrations of NEFA, IGF-1, urea, 
triglyceride, cortisol, and insulin (Figure 4) remained 
unchanged in both HyperB and control groups dur-
ing the course of infusion. The plasma urea, IGF-1, 
and triglycerides decreased within control group, and 
the plasma glucose and urea decreased within HyperB 
group.
Liver Gene Expression
The mRNA abundance in liver of the studied vari-
ables did not differ between treatments (Table 5). 
β-Hydroxybutyrate infusion affected abundance of 
PRKAA1on mRNA and tended to be lower in the Hy-
perB group than the control group (P = 0.08). The 
mRNA abundance of PC increase and that of pyruvate 
dehydrogenase (lipomide) α 1, and HMGCS1 decreased 
(P < 0.05) over time within the control cows. In the 
HyperB group, the mRNA abundance of HMGCS1 
decreased significantly over time.
DISCUSSION
The objective was to induce an elevated plasma con-
centration of BHBA, without the metabolic situation 
as observed during the early lactation, to solely inves-
tigate the effect of BHBA on feed intake, milk yield, 
and metabolism. To the best of our knowledge, this 
study is the first that has induced an elevated plasma 
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Figure 1. β-Hydroxybutyrate infusion rate during 48-h infusion in BHBA cows (HyperB). Plasma BHBA concentration in control cows and 
cows infused with BHBA before the start of the infusion (d 0) and during 48-h infusion. Values represent mean ± SEM.
Table 2. Least squares means ± SEM of area under the curve for plasma variables concentration in dairy cows 
infused with BHBA (HyperB) or saline (NaCl) on d 2 
Variable Group LSM ± SEM d 2
ANOVA  
(P-value, group)
Glucose (mmol/L) HyperB 3.47 ± 0.11 <0.01
NaCl 4.11 ± 0.08
Insulin (mU/L) HyperB 12.7 ± 1.4 0.54
NaCl 13.9 ± 1.1
BHBA (mmol/L) HyperB 1.74 ± 0.02 <0.001
NaCl 0.59 ± 0.02
NEFA (mmol/L) HyperB 0.06 ± 0.03 0.51
NaCl 0.09 ± 0.02
Urea (mmol/L) HyperB 3.77 ± 0.31 0.63
NaCl 3.97 ± 0.24
Glucagon (pg/mL) HyperB 97.4 ± 3.3 <0.05
NaCl 107.7 ± 2.6
IGF-1 (ng/mL) HyperB 90 ± 4.5 0.11
NaCl 80 ± 3.6
Triglycerides (mmol/L) HyperB 0.15 ± 0.01 0.58
NaCl 0.14 ± 0.01
Cortisol (ng/mL) HyperB 2.41 ± 0.55 0.78
NaCl 2.62 ± 0.43
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BHBA concentration for 48 h in dairy cows by infusion 
of BHBA. The plasma BHBA concentration reached 
was 1.7 ± 0.1 mmol/L, which was clearly above the 
considered concentration of 1.2 to 1.4 mmol/L referring 
to subclinical ketosis (Duffield et al., 2009; Ospina et 
al., 2010).
The expected reduction of DMI in HyperB cows, 
as shown in cows with spontaneously elevated ketone 
body concentrations (Bareille et al., 2003; González et 
al., 2008), was not observed in our study. Subcutane-
ous injection of BHBA (10 mmol/kg of BW) in rats 
(Moor et al., 1976; Langhans et al., 1983), intraperito-
neal BHBA infusion (15 mmol/kg0.75) in pigmy goats 
(Rossi et al., 2000), and intracerebroventricular BHBA 
infusion (18mM/d) in dairy cows (Kuhla et al., 2011) 
decreased feed intake. β-Hydroxybutyrate can play 
a role in the regulation of feed intake (Langhans et 
al., 1983). In an in vitro experiment, elevation of the 
BHBA to glucose ratio to 1:1 in early lactation, com-
pared to nonketotic cows with a 1:4 ratio, can decrease 
feed intake via stimulation of dephosphorylation of 
5? adenosine monophosphate-activated protein kinase 
(AMPK) after parturition (Laeger et al., 2012). In the 
current study, BHBA infusion did not affect feed intake 
throughout the experiment, which may relate to a low 
ratio of BHBA to glucose.
During the experiment plasma glucose concentra-
tion decreased dramatically due to the infusion of 
BHBA. This finding is consistent with other reports 
of decreased plasma glucose concentration associated 
with elevated BHBA in pregnant sheep (Schlumbohm 
and Harmeyer 2003, 2004), dogs (Felts et al., 1964; 
Madison et al., 1964), and pigs (Müller et al., 1984). 
However, our findings are in contrast to other reports 
that described a hyperglycemia in rabbits (Mirsky and 
Broh- Kahn, 1937) induced by ketone bodies infusion.
Table 3. Milk yield, ECM, DMI, and energy balance (EB) of dairy cows infused with BHBA (HyperB) or 
saline (NaCl) before the start of the infusion (d 0) and difference (Δ d 2–d 0) between before and after 48-h 
infusion (d 2); values represent mean ± SEM 
Variable Group d 0 Δ d 2–d 0
ANOVA  
(P-value, group)
Milk yield (kg/d) HyperB 23.31 ± 0.78 −3.30 ± 1.43* 0.3
NaCl 21.78 ± 2.53 −1.76 ± 0.68
ECM (kg/d) HyperB 21.00 ± 0.28 −1.58 ± 0.76 0.79
NaCl 21.95 ± 2.58 −1.21 ± 0.85
DMI (kg/day) HyperB 19.82 ± 0.66 −0.80 ± 1.22 0.76
NaCl 18.33 ± 1.28 −0.38 ± 0.76
EB (MJ/d) HyperB 15.04 ± 2.18 −1.04 ± 8.67 0.77
NaCl 1.67 ± 4.90 1.72 ± 4.90
*Delta is different from 0 (P < 0.05).
Table 4. Plasma variables concentrations in dairy cows infused with BHBA (HyperB) or saline (NaCl) before 
the start of the infusion (d 0) and difference (Δ d 2–d 0) between before and after 48-h infusion (d 2); values 
represent mean ± SEM 
Variable Group d 0 Δ d 2–d 0
ANOVA  
(P-value, group)
Glucose (mmol/L) HyperB 4.10 ± 0.08 −0.46 ± 0.18* <0.05
NaCl 3.87 ± 0.08 0.10 ± 0.14
Insulin (mU/L) HyperB 8.74 ± 0.78 −1.56 ± 0.92 0.30
NaCl 6.78 ± 1.62 0.14 ± 1.08
BHBA (mmol/L) HyperB 0.51 ± 0.05 0.74 ± 0.15* <0.001
NaCl 0.42 ± 0.04 0.09 ± 0.05
NEFA (mmol/L) HyperB 0.11 ± 0.02 −0.02 ± 0.02 0.7
NaCl 0.16 ± 0.03 −0.04 ± 0.04
Urea (mmol/L) HyperB 4.73 ± 0.34 −1.25 ± 0.3* 0.73
NaCl 5.0 ± 0.26 −1.05 ± 0.4*
IGF-1 (ng/mL) HyperB 91 ± 6.1 −6.65 ± 2.5 0.55
NaCl 100 ± 10.0 −9.87 ± 3.7*
Glucagon (pg/mL) HyperB 115.2 ± 19.1 −17.3 ± 1.3* 0.06
NaCl 109.6 ± 5.4 −1.0 ± 6.1
Triglycerides (mmol/L) HyperB 0.18 ± 0.01 −0.02 ± 0.01 0.91
NaCl 0.16 ± 0.01 −0.02 ± 0.01*
Cortisol (ng/mL) HyperB 5.74 ± 1.4 −2.37 ± 1.9 0.67
NaCl 2.92 ± 0.8 −1.56 ± 0.9
*Delta is different from 0 (P < 0.05).
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Information about the reasons for decreased plasma 
glucose concentration due to the elevated BHBA con-
centration is limited; hypothetically, insulin plays a role 
in this effect. Infusion of BHBA increases insulin secre-
tion in pigs (Müller et al., 1984). Madison et al. (1964) 
suggested that pancreatic beta cells respond to the high 
plasma BHBA concentration with increased insulin se-
cretion in dogs. It appears that insulin suppresses the 
glucose production throughout an inhibitory effect on 
the regulatory enzymes of gluconeogenesis (Brockman 
and Larrveld, 1986; Hayirli, 2006). This release of en-
dogenous insulin can lead to a decline in plasma glucose 
concentration and reduce hepatic glucose production. 
The unchanged insulin concentration in response to the 
BHBA infusion in the present study may be explained 
by the fact that ketone bodies represent only a modest 
stimulus on insulin secretion in ruminants (Jordan and 
Philips, 1978; Heitmann and Fernandez, 1986). Insulin 
obviously did not play a significant role in mediating 
the lowering effect of BHBA on plasma glucose concen-
tration in sheep (Schlumbohm and Harmeyer, 2003). 
Decreased glucose concentration and hepatic glucose 
output due to the infusion of BHBA can reduce the 
availability of glucose for the peripheral tissues because 
exhausted glucose stores must be replaced by a catabo-
lism of proteins during emergency conditions for the 
vital tissues, such as central nervous system (Madison 
et al., 1964). The molarity of ketone bodies in plasma 
is the same or higher than that of glucose. Thus, en-
hanced plasma BHBA concentration can increase the 
efficiency of BHBA as a competitor to glucose used 
by peripheral tissues, and has been shown to inhibit 
peripheral glucose utilization (Madison et al., 1964). 
Glucose is required as a unique source for mammary 
lactose synthesis or energy for red blood cells. However, 
during limited glucose availability in the body, extra 
hepatic tissues (e.g., brain) can use ketone bodies as 
an alternative fuel, and ketone bodies have a glucose-
sparing effect in the tissues where they can be used 
as energy source. Mebane and Madison (1962) dem-
onstrated that ketone body infusion leads to a 30% 
reduction in glucose utilization by peripheral tissues. 
Previous studies also reported that the oxidation of 
glucose was inhibited by ketone body infusion (Neptune 
Figure 2. Plasma glucose concentration in control cows and cows infused with BHBA (HyperB) before the start of the infusion (d 0) and 
during 48-h infusion. Values represent mean ± SEM.
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et al., 1961; Williamson and Krebs, 1961). In contrast, 
as mentioned previously, Schlumbohm and Harmeyer 
(2004) suggested that BHBA infusion decreased en-
dogenous glucose production but did not affect glucose 
utilization in pregnant sheep. Furthermore, they sug-
gested that the elevated concentration of ketone bodies 
in blood initially decreases glucose production via the 
depressed signal on hepatic gluconeogenesis in liver.
In contrast to a previous study that found increased 
glucagon concentrations after BHBA infusion in pigs 
(Müller et al., 1984), in the current study BHBA infu-
sion decreased glucagon concentration in HyperB com-
pared with the control group. Plasma glucose is derived 
from the feed, glycogen, and by gluconeogenesis, and 
it is regulated by several hormones, mainly glucagon 
and insulin. Glucagon increases plasma glucose con-
centration through stimulation of gluconeogenesis and 
glycogenolysis (Aronoff et al., 2004; Taborsky, 2010). 
Changes in glucagon secretion from the physiological 
range results in changes of plasma glucose concentra-
tion (Taborsky, 2010); some substrates, such as NEFA 
and ketone bodies, suppress glucagon secretion (Gerich 
et al., 1974;1976; Goberna et al., 1974). Evidence exists 
that glucagon secretion is inhibited by the neighbor-
ing beta cell through insulin (Weir et al., 1976) and 
γ-aminobutyric acid (GABA; Adeghate et al., 2000; 
Wendt et al., 2004). γ-Aminobutyric acid is an inhibi-
tory neurotransmitter in the brain. In an in vitro study 
it was demonstrated that BHBA increases GABA con-
centration in the epileptic brain (Suzuki et al., 2009). 
Therefore, it can be hypothesized that the decrease in 
glucagon concentration in the current study is related 
to elevated BHBA concentration—as BHBA is used as 
an alternative fuel and energy source for the tissues—
or glucagon secretion was inhibited by GABA, whose 
concentration likely increased during elevated BHBA. 
Subsequently, a decline of glucagon secretion decreased 
glucose production through the effect on glycogenolysis 
or gluconeogenesis during the experiment. A decrease of 
plasma NEFA concentration was expected in response 
Figure 3. Plasma glucagon concentration in control cows and cows infused with BHBA (HyperB) before the start of the infusion (d 0) and 
during 48-h infusion. Values represent mean ± SEM.
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to the BHBA infusion and a subsequent increase of 
insulin (Madison et al., 1964); however, both variables 
did not change during the experimental period.
β-Hydroxybutyrate can replace glucose to be utilized 
in peripheral tissues (Madison et al., 1964), which can 
also potentially contribute to reduced FA mobilization 
from adipose tissues. Conversely, after a decline in 
glucose during negative energy balance, NEFA plasma 
concentration increased in early lactation (van Dorland 
et al., 2009). The main difference of the current study 
from the previous one is the absence of negative energy 
balance despite decreased glucose, with the respective 
differences of insulin secretion. However, as the main 
site of ketone body synthesis from fatty acid oxidation, 
the liver cannot utilize ketone bodies for the synthesis 
of acetoacetyl CoA, and subsequently FA, due to a lack 
of succinyl-CoA:3-ketoacid-coenzyme A transferase 1, 
mitochondrial (Goodridge and Sul, 2000).
Effects of BHBA Infusion  
on Hepatic Gene Expression
The present results of mRNA abundance of key en-
zymes related to hepatic gluconeogenesis (PC, glucose-
6-phosphatase, mitochondrial phosphoenolpyruvate 
carboxykinase) are in contrast with suggestions from 
previous studies that indicated an inhibition of gluco-
neogenesis by elevated plasma BHBA concentration 
(Müller et al., 1984; Schlumbohm and Harmeyer, 2003). 
Müller et al. (1984) suggested that ketone bodies prob-
ably have a direct inhibitory action on gluconeogenesis. 
They mentioned that the effect of ketone bodies on 
endogenous glucose production is probably mediated 
by insulin. However, in ruminants, the effect of ke-
tone bodies on insulin secretion is not strong (Jordan 
and Philips, 1978; Heitmann and Fernandez, 1986), 
and insulin concentration did not change in the cur-
rent study. Soling and Kleineke (1976) suggested that 
ketone bodies have a glucose-sparing effect in tissues 
through the mitochondrial formation of citrate, an al-
losteric inhibitor, phosphofructo-1,6-kinase, acetyl-CoA 
inhibition of pyruvate dehydrogenase and activation of 
PC. β-Hydroxybutyrate infusion did not affect key en-
zymes related to gluconeogenesis, glycolysis, pyruvate 
dehydrogenase complex, and citrate synthase mRNA 
expression. According to the mRNA abundance of some 
enzymes related to FA oxidation, BHBA infusion did 
Figure 4. Plasma insulin concentration in control cows and cows infused with BHBA (HyperB) before the start of the infusion (d 0) and 
during 48-h infusion. Values represent mean ± SEM.
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not affect FA oxidation. These results are not in agree-
ment with previous reports (Soling and Kleineke, 1976; 
Morio and Wolfe, 2005) that mentioned ketone bodies 
are an inhibitor for FA oxidation through increase acetyl 
CoA production, inhibit carnitine palmitoyltransferase 
activity, and stimulate malonyl CoA synthesis.
As mentioned previously, ketone bodies suppressed 
the glucagon secretion, and this inhibition could have 
been regulated via cyclic AMP. The mechanism of this 
inhibition is related to the generation of ATP or ADP 
by substrate, such as ketone bodies, then decrease of 
cAMP, and finally prevention of glucagon secretion 
Table 5. Liver mRNA expression in dairy cows infused with BHBA (HyperB) or saline (NaCl) before the start of the infusion (d 0) and 
difference (Δ d 2–d 0) between before and after 48-h infusion (d 2); values represent mean ± SEM 




 G6PC HyperB 22.89 ± 0.46 −0.57 ± 0.50 0.44
NaCl 21.05 ± 0.49 −0.18 ± 0.24
 PC HyperB 17.42 ± 0.22 0.43 ± 0.08 0.87
NaCl 17.57 ± 0.13 0.48 ± 0.23*
 PEPCKm HyperB 14.60 ± 0.43 0.46 ± 0.29 0.18
NaCl 14.85 ± 0.20 −0.21 ± 0.32
Phosphofructokinase, liver and lactate dehydrogenase
 LDHA HyperB 16.58 ± 0.22 −0.58 ± 0.32 0.80
NaCl 16.50 ± 0.30 −0.45 ± 0.34  
 LDHB HyperB 19.47 ± 0.32 0.01 ± 0.18 0.52
NaCl 19.68 ± 0.38 −0.36 ± 0.45  
 PFKL HyperB 15.00 ± 0.25 0.35 ± 0.37 0.35
NaCl 15.38 ± 0.21 −0.22 ± 0.40  
Glucagon receptor, glycogen synthase,  
protein kinase AMP-activated α 1
 GCGR HyperB 17.92 ± 0.19 −0.33 ± 0.24 0.91
NaCl 16.98 ± 0.56 −0.24 ± 0.28
 GYS2 HyperB 19.03 ± 0.28 −0.90 ± 0.35 0.83
NaCl 17.56 ± 0.49 −0.57 ± 0.29
 PRKAA1 HyperB 15.19 ± 0.22 −0.57 ± 0.30 0.08
NaCl 14.11 ± 0.36 0.11 ± 0.21
Pyruvate dehydrogenase complex variables
 DBT HyperB 18.19 ± 0.18 −0.09 ± 0.23 0.90
NaCl 17.64 ± 0.27 −0.21 ± 0.68
 DLD HyperB 18.14 ± 0.17 −0.52 ± 0.31 0.84
NaCl 17.90 ± 0.14 −0.38 ± 0.48
 PDHA1 HyperB 17.94 ± 0.14 −0.58 ± 0.46 0.53
NaCl 18.09 ± 0.17 −1.03 ± 0.46*
FA and cholesterol synthesis-related variables
 ACoAC HyperB 10.41 ± 0.18 −0.44 ± 0.34 0.64
NaCl 8.66 ± 0.51 −0.74 ± 0.43
 FASN HyperB 14.0 ± 0.4 −0.8 ± 0.3 0.82
NaCl 14.0 ± 0.51 −0.9 ± 0.5
 HMGCS1 HyperB 20.95 ± 0.24 −1.61 ± 0.51* 0.69
NaCl 18.84 ± 0.46 −1.24 ± 0.60*
FA oxidation-related variables
 ACSL HyperB 19.76 ± 0.17 0.05 ± 0.19 0.65
NaCl 18.87 ± 0.49 −0.07 ± 0.16
 CPT1 HyperB 14.82 ± 0.22 −0.28 ± 0.29 0.55
NaCl 13.16 ± 0.36 −0.09 ± 0.16
 CPT2 HyperB 18.07 ± 0.12 −0.33 ± 0.10 0.54
NaCl 17.19 ± 0.29 −0.46 ± 0.14
Citrate synthase, and ketogenesis-related variables
 CS HyperB 14.48 ± 0.06 −0.26 ± 0.15 0.91
NaCl 12.77 ± 0.40 −0.23 ± 0.20
 HMGCS2 HyperB 21.62 ± 0.33 −0.23 ± 0.33 0.77
NaCl 21.14 ± 0.32 −0.10 ± 0.29
1G6PC = glucose-6-phosphatase; PC = pyruvate carboxylase; PEPCKm = mitochondrial phosphoenolpyruvate carboxykinase; LDHA = lac-
tate dehydrogenase A; LDHB = lactate dehydrogenase B; PFKL = phosphofructokinase liver; GCGR = glucagon receptor; GYS2 = glycogen 
synthase 2; PPKA1 = protein kinase AMP-activated α 1; DBT = dihydrolipoamide branched chain transacylase E2; DLD = dihydrolipoamide 
dehydrogenase; PDHA1 = pyruvatedehydrogenase (lipomide) α 1; ACoAC = acetyl-CoA carboxylase; FASN = fatty acid synthase; HMGCS1 = 
3-hydroxyl-3 – methylglutaryl-CoA synthase 1; ACSL1 = acyl-CoA synthetase long-chain; CPT1A = carnitine palmitoyltransferase 1A; CPT2 
= carnitine palmitoyltransferase 2; CS = citrate synthase; HMGCS2 = 3-hydroxyl-3-methylglutaryl-CoA synthase 2.
*Delta is different from 0 (P < 0.05).
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(Toyota et al., 1975; Gerich et al., 1976; Mitrakou et 
al., 1991; Adeghate et al., 2000). In the present study, 
the PRKAA1 expression tended to decrease in HyperB 
compared with control group (P < 0.1). Conversely, 
BHBA infusion decreased the PRKAA1 expression, 
and subsequently glucagon excretion was decreased.
CONCLUSIONS
Results from this study demonstrate that intravenous 
BHBA infusion successfully induced elevated plasma 
BHBA concentration over 48 h in dairy cows. Feed 
intake was not affected by elevated BHBA concentra-
tion during a period when energy balance is positive. 
Decreased plasma glucose concentration during BHBA 
administration cannot be related to changes of insulin 
concentration or to mRNA abundance of genes related 
to hepatic gluconeogenesis, FA synthesis, citrate syn-
thase, pyruvate dehydrogenase complex, and glycolysis. 
Although mRNA expression indicated high activity of 
enzyme production, the effects of BHBA infusion most 
likely occurred at a posttranscriptional level. Reduced 
glucose concentration may be related to a decrease in 
plasma glucagon concentration, which can decrease 
glucose production from gluconeogenesis or glycogen 
storage. Thus, BHBA seems to have a glucose-sparing 
effect. However, glucose entry rate was probably re-
duced by the treatment, and additional studies will be 
necessary to clarify the underlying mechanisms.
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